On November 9, HUTCHMED rose 5.18% in regular trading, trading at HK$24.38, with turnover of HK$58.34 million.
The clearest recent catalyst is an event-driven rerating: Citi maintained its buy/high-risk view, raised its target price to HK$43.2 from HK$40.1, and named HUTCHMED its new top pick.
The upgrade followed an expert call held on November 5 with a principal investigator from the SANOVO study, which reinforced Citi's positive view on savolitinib in first-line and post-osimertinib EGFR-mutated non-small cell lung cancer. Citi also raised its revenue forecasts for fiscal years 2027 and 2028 by 4% and 2%, and lifted EPS estimates by 15% and 5%, mainly reflecting potential overseas approval of savolitinib and epidemiology model adjustments. Supporting recent news flow also included FDA orphan-drug designation for sovleplenib in autoimmune hemolytic anemia, its second such designation in the US within days, and continued global regulatory progress for the ORPATHYS plus TAGRISSO combination.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments